journal
MENU ▼
Read by QxMD icon Read
search

Hematological Oncology | Page 2

journal
https://read.qxmd.com/read/31283840/prolonged-follow-up-on-lenalidomide-based-treatment-for-mucosa-associated-lymphoid-tissue-lymphoma-malt-lymphoma-real-world-data-from-the-medical-university-of-vienna
#21
Barbara Kiesewetter, Wolfgang Lamm, Ortrun Neuper, Marius E Mayerhoefer, Ingrid Simonitsch-Klupp, Markus Raderer
Based on results of two pilot trials, lenalidomide (LEN) was found to be active and safe as monotherapy and showed an increased response rate of 80% in combination with rituximab (R) for patients with MALT lymphoma. While initial results were promising, there are currently no data on long-term outcome and larger international phase II/III trials on LEN for indolent lymphoma lack specific subgroup analyses. Thus, we have systematically analyzed 50 patients treated with LEN-based therapy (LEN-monotherapy n = 16, R-LEN n = 34) at the Medical University of Vienna 2009-2019 and investigated long-term outcome and relapse patterns...
July 8, 2019: Hematological Oncology
https://read.qxmd.com/read/31251400/optimizing-venetoclax-dose-in-combination-with-low-intensive-therapies-in-elderly-patients-with-newly-diagnosed-acute-myeloid-leukemia-an-exposure-response-analysis
#22
Suresh Agarwal, Sathej Gopalakrishnan, Sven Mensing, Jalaja Potluri, John Hayslip, Whitney Kirschbrown, Anna Friedel, Rajeev Menon, Ahmed Hamed Salem
The objective of this research was to characterize the venetoclax exposure-efficacy and exposure-safety relationships and determine its optimal dose in elderly patients with newly diagnosed acute myeloid leukemia (AML) receiving venetoclax in combination with low intensity therapies (hypomethylating agent (HMA; azacitidine or decitabine) or low-dose cytarabine (LDAC)). A total of 212 patients from the HMA study and 92 patients from the LDAC study were included in the exposure-safety analyses. Those who received at least one dose of venetoclax and had at least one measurable response (201 and 83, in the HMA and LDAC studies, respectively) were included in the exposure-efficacy analyses...
June 28, 2019: Hematological Oncology
https://read.qxmd.com/read/31339579/brentuximab-vedotin-and-anti-pd1-treatment-optimize-survival-in-chemo-refractory-hodgkin-lymphoma-patients-real-world-data
#23
LETTER
Ioanna Sakellari, Eleni Gavriilaki, Michail Iskas, Zoi Bousiou, Aristotelis Chatziioannidis, I Batsis, Despina Mallouri, Varnavas Constantinous, Niki Stavroyianni, Antonia Syrigou, Anastasia Marvaki, Maria Pilavaki, Styliani Papaemmanouel, Achilles Anagnostopoulos
No abstract text is available yet for this article.
June 10, 2019: Hematological Oncology
https://read.qxmd.com/read/31187537/new-drugs-for-old-targets
#24
REVIEW
Gilles Salles
In recent years, many new antibodies, either naked or armed with toxin or radionuclides have been investigated to enhance the field of active agents directed against already identified ("old") targets. This was particularly the case for the antigens CD19 and CD20 but also some other ones. The success of these developments has been variable and underlines the need to better characterize the mode of action of these molecules. Combinations studies of these new agents with other molecules, in particular those with an immunomodulatory potential, are also currently developed with some promising results...
June 2019: Hematological Oncology
https://read.qxmd.com/read/31187536/what-we-should-know-about-natural-killer-t-cell-lymphomas
#25
REVIEW
Jie Xiong, Weili Zhao
Natural-killer/T cell lymphoma (NKTCL) is the most common extranodal lymphoma with highly aggressive clinical outcome. System biology techniques provide novel insights into the pathogenesis, risk stratification, and clinical management in NKTCL. Comparative genomic hybridization analysis reveal most frequent deletion of chromosome 6q21. Whole-exome sequencing studies identify recurrent somatic gene mutations, involving RNA helicases, tumor suppressors, JAK-STAT pathway molecules, and epigenetic modifiers. Genome-wide association study reports strongest association of HLA-DPB1 rs9277378 with lymphomagenesis...
June 2019: Hematological Oncology
https://read.qxmd.com/read/31187535/managing-the-toxicities-of-car-t-cell-therapy
#26
REVIEW
Sattva S Neelapu
Chimeric antigen receptor (CAR) T-cell therapy has the potential to revolutionize the management of B-cell lymphomas and possibly other cancers. Two anti-CD19 CAR T-cell products, axicabtagene ciloleucel and tisagenlecleucel, have been approved for the management of relapsed/refractory large B-cell lymphoma after two lines of systemic therapy. Additional trials are ongoing to evaluate these and other CAR T products at earlier stages of the disease course as well as in other lymphomas. While the potential to induce durable remissions with a single CAR T-cell infusion even in patients who are chemorefractory has generated much enthusiasm in the field, practitioners need to familiarize themselves with the unique toxicities associated with these therapies...
June 2019: Hematological Oncology
https://read.qxmd.com/read/31187534/cutaneous-lymphomas-an-update-2019
#27
Werner Kempf, Anne-Katrin Zimmermann, Christina Mitteldorf
Primary cutaneous lymphomas (CL) are the second most common form of extranodal lymphomas. Cutaneous T-cell lymphomas represent the majority. They are classified according to the WHO classification 2017 and the updated WHO-EORTC 2018 published in the fourth edition of the WHO classification for Skin Tumors monograph. Primary cutaneous acral CD8+ T-cell lymphoma and EBV-positive mucocutaneous ulcer have been listed as new provisional entities. Moreover, the histological and genetic spectrum of lymphomatoid papulosis has been expanded...
June 2019: Hematological Oncology
https://read.qxmd.com/read/31187533/car-t-cell-therapy-full-speed-ahead
#28
David Sermer, Renier Brentjens
Chimeric antigen receptor (CAR) T-cell therapy has dramatically shifted the landscape of treatment for lymphoid malignancies, especially diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukemia (ALL). However, there continue to be significant limitations of this therapy, such as incomplete or nonsustained responses and severe toxicities in a subset of patients. Furthermore, expanding the role of CAR T-cell therapy to new disease types is an important next step. In this review, we will highlight landmark trials for anti-CD19 CAR T cells and first-in-human trials of novel CARs, as well as discuss promising innovative CAR designs that are still undergoing preclinical development...
June 2019: Hematological Oncology
https://read.qxmd.com/read/31187532/treating-hodgkin-lymphoma-in-the-new-millennium-relapsed-and-refractory-disease
#29
REVIEW
Ann S LaCasce
Although the majority of patients with Hodgkin lymphoma are cured with initial therapy, 10% to 15% of patients with early stage disease and 15% to 30% of patients with advanced disease have primary refractory or relapsed lymphoma. For younger patients whose disease is sensitive to second-line therapy, more than half of patients will experience long-term disease control with high-dose chemotherapy/autologous stem cell rescue (ASCT). For those patients who are chemotherapy refractory, relapse after, or are ineligible for ASCT, brentuximab vedotin, and checkpoint, inhibitors are highly active, although the majority of patients will ultimately experience recurrent lymphoma...
June 2019: Hematological Oncology
https://read.qxmd.com/read/31187531/the-modern-approach-to-mantle-cell-lymphoma
#30
REVIEW
Simon Rule
Mantle Cell Lymphoma is a rare and generally aggressive form of non Hodgkin lymphoma. Our understanding of the pathophysiology of this disease is improving and whilst risk factors are understood, treatments are not yet tailored towards these. The treatment algorithm in the front line is well established for older and younger patients and observation is the norm for a subset of patients although these are not well characterised as yet. In the relapse setting the role of novel agents, especially the BTK inhibitors is becoming established and combination approaches look promising...
June 2019: Hematological Oncology
https://read.qxmd.com/read/31187530/rare-mature-b-cell-lymphomas-in-children-and-adolescents
#31
REVIEW
Wilhelm Woessmann, Leticia Quintanilla-Martinez
Pediatric-type follicular lymphoma (PTFL), pediatric nodal marginal zone lymphoma (pnMZL), and large B-cell lymphoma (LBCL) with IRF4 rearrangement have been introduced into the current World Health Organization (WHO) classification. They account for 5% to 10% of mature B-cell lymphomas in children and adolescents. Both PTFL and pnMZL predominantly affect male adolescents and usually present with localized lymphadenopathy in the head and neck region. The cells within the follicles of PTFL typically show high-grade cytology, IGH monoclonality and lack the t(14;18) chromosomal alteration...
June 2019: Hematological Oncology
https://read.qxmd.com/read/31187529/new-drugs-for-new-targets-in-lymphoma
#32
Anas Younes
No abstract text is available yet for this article.
June 2019: Hematological Oncology
https://read.qxmd.com/read/31187528/double-hit-lymphoma-so-what
#33
Andrew Davies
The revised WHO classification moved all aggressive B-cell lymphomas with a MYC translocation and a concurrent translocation of BCL2 and/or BCL6 into a single diagnostic category. These are the double- and triple-hit lymphomas. These represent a group with typically a poor outcome to conventional therapy, and as a result, intensification of immunochemotherapy has been explored. The optimal approach is far from clear, and recent insight into the biology suggest that they may represent just a subgroup of molecular high-grade B-cell lymphomas that maybe identified by gene expression profiling...
June 2019: Hematological Oncology
https://read.qxmd.com/read/31187527/options-for-first-line-therapy-of-hodgkin-lymphoma
#34
Jemma Longley, Peter W M Johnson
No abstract text is available yet for this article.
June 2019: Hematological Oncology
https://read.qxmd.com/read/31187526/multiple-myeloma-every-year-a-new-standard
#35
REVIEW
S Vincent Rajkumar
The treatment of myeloma is rapidly evolving. This article reviews the current diagnostic criteria, risk stratification, and approach to treatment of multiple myeloma. Treatment approach for both newly diagnosed and relapsed disease are discussed.
June 2019: Hematological Oncology
https://read.qxmd.com/read/31187525/15th-international-conference-on-malignant-lymphoma-palazzo-dei-congressi-lugano-switzerland-18-22-june-2019
#36
(no author information available yet)
No abstract text is available yet for this article.
June 2019: Hematological Oncology
https://read.qxmd.com/read/31187524/breast-implant-associated-anaplastic-large-cell-lymphoma-and-other-rare-t-cell-lymphomas
#37
Laurence de Leval
No abstract text is available yet for this article.
June 2019: Hematological Oncology
https://read.qxmd.com/read/31187523/primary-central-nervous-system-lymphoma-a-curable-disease
#38
REVIEW
Tracy T Batchelor
Primary central nervous system lymphoma is a rare subtype of non-Hodgkin lymphoma that is confined to the brain, leptomeninges, or the eye and is associated with a relatively poor prognosis compared to other extranodal diffuse large B-cell lymphomas. However, methotrexate-based induction chemotherapy followed by consolidative chemotherapy or high-dose therapy and autologous stem cell transplantation is associated with improved survival and reduced neurotoxicity. Aberrant activation of B-cell receptor signaling and activation of nuclear factor kappa beta is a frequent genetic alteration and offers opportunities for targeted therapies in this lymphoma subtype...
June 2019: Hematological Oncology
https://read.qxmd.com/read/31187522/liquid-biopsy-in-non-hodgkin-s-lymphoma
#39
REVIEW
Christopher Melani, Wyndham H Wilson, Mark Roschewski
ctDNA provides an important new strategy that will aid in the treatment of non-Hodgkin's lymphoma. Immunoglobulin sequencing provides a tumor specific marker for disease activity with a sensitivity equivalent to one tumor cell per 10-6. Furthermore, it can provide an estimate of tumor bulk and tumor response dynamics during treatment. Interim monitoring can identify patients at high risk of treatment failure and surveillance monitoring can identify patients months before radiographic disease progression. Tumor specific mutations can also be detected in ctDNA and may reflect an averaging of mutations present within multiple tumor masses...
June 2019: Hematological Oncology
https://read.qxmd.com/read/31187521/new-treatment-options-in-hairy-cell-leukemia-with-focus-on-braf-inhibitors
#40
REVIEW
Brunangelo Falini, Enrico Tiacci
Hairy cell leukemia (HCL) responds initially very well to chemotherapy with purine analogues. However, up to 50% of patients relapse, often multiple times, and become progressively less sensitive to these myelotoxic and immune-suppressive drugs. At progression, viable therapeutic strategies include addition of rituximab to purine analogues, and treatment with the anti-CD22 immunotoxin moxetumomab pasudotox, which has been recently approved by the FDA in HCL patients after at least two prior therapies. Identification of the BRAF-V600E kinase mutation as the genetic cause of HCL has opened the way, in the relapsed/refractory experimental setting, to targeted and non-myelotoxic effective strategies that are based on inhibition of BRAF with vemurafenib, co-inhibition of BRAF and its target MEK with dabrafenib and trametinib, and BRAF inhibition with vemurafenib combined with anti-CD20 immunotherapy...
June 2019: Hematological Oncology
journal
journal
28626
2
3
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"